Life sciences deals often involve complex earn-out structures, billion-dollar valuations, and cross-border considerations, making them fertile ground for disputes. This panel brings together dealmakers, counsel, and arbitrators to explore how arbitration is shaping the resolution of M&A disputes in this sector. From drafting pitfalls to jurisdictional and procedural choices, to recurring substantive issues, we’ll examine what’s driving disputes and how parties can mitigate risk in high-stakes transactions.